Search Results
Your search for ,WHo matches 20416 pages
Showing 5101 - 5150Do Diet-Related Molecules Play a Role in the Development of Aggressive Prostate Cancer?
Cleveland Clinic researchers have shown that diet-associated molecules in the gut may be associated with aggressive prostate cancer, suggesting dietary interventions may help reduce risk. These findings were published by Reichard et al in Cancer Epidemiology, Biomarkers & Prevention. While...
Study Finds Incidence of Pancreatic Cancer May Be Rising in Younger Women
The incidence of pancreatic cancer—which historically has been higher in men than in women—has increased among both men and women during the past decade, with a significantly greater relative increase observed in women younger than age 55 years, and especially among those aged 15 to 34 years. These ...
Integrated Molecular-Morphologic Risk Predictor for Recurrence of Meningioma
In a study reported in the Journal of Clinical Oncology, Maas et al developed a novel integrated molecular-morphologic risk classification score that improved prediction of disease recurrence in patients with meningioma. Study Details The study involved DNA methylation, copy-number, and mutation...
Rates of Occult Gastric Carcinoma in Patients With Hereditary Lobular Breast Cancer Due to CDH1 Genetic Variants
In a single-institution prospective cohort study reported in JAMA Surgery, Gamble et al found that patients with hereditary lobular breast cancer due to CDH1 variants also had a high prevalence of occult signet ring cell gastric carcinoma. Study Details The study involved 283 patients from 151...
Patients With Multiple Myeloma May Lack T-Cell Responses to COVID-19 Vaccination
Patients with multiple myeloma lacking an antibody response to COVID-19 vaccine may also fail to mount a T-cell response, according to research from the Icahn School of Medicine at Mount Sinai. Concerningly, this scenario was most common among patients actively treated with anti-CD38 and...
Study Finds Similar Survival Rates Among Patients With Metastatic Colorectal Cancer Younger and Older Than Age 50
Even though patients with metastatic colorectal cancer younger than age 50 tend to be more fit and receive more intensive treatment than older patients, survival for both groups is roughly the same, according to a study published by Lipsyc-Sharf et al in the Journal of the National Cancer...
Addition of Enasidenib to Azacitidine in Newly Diagnosed IDH2-Mutant Acute Myeloid Leukemia
As reported in The Lancet Oncology by Courtney D. DiNardo, MD, and colleagues, an interim analysis of the phase II portion of a phase Ib/II trial (AG221-AML-005) showed that the addition of the oral mutant IDH2 protein inhibitor enasidenib to azacitidine significantly improved overall response rate ...
Nivolumab for Relapsed Malignant Mesothelioma: Improvements in Progression-Free and Overall Survival
In the phase III CONFIRM trial reported in The Lancet Oncology, Dean A. Fennell, FRCP, PhD, and colleagues found that nivolumab improved progression-free and overall survival vs placebo in patients with relapsed malignant mesothelioma. In October 2020, the combination of nivolumab and ipilimumab...
Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: Treatment-Related Cardiotoxicity
Youssef Zeidan, MD, PhD, of Florida International University and the Lynn Cancer Institute, discusses the advances in radiotherapy planning and delivery that have reduced cardiac radiation exposure in patients with HER2-positive breast cancer who are treated with radiotherapy and trastuzumab...
Phase III Trial Evaluates Efficacy of Total Androgen Suppression Plus Dose-Escalated Radiotherapy for Patients With Intermediate-Risk Prostate Cancer
Both dose-escalated radiation therapy and short-course androgen-deprivation therapy (SADT) have been shown to improve outcomes in patients with intermediate-risk prostate cancer. Researchers then posed a new question—is giving both modalities upfront to newly diagnosed patients of benefit? Findings ...
Expert Point of View: Pierre Laurent-Puig, MD
The invited discussant of the FOCUS4-C trial was Pierre Laurent-Puig, MD, Professor of Medicine, Université de Paris, Institut du Cancer Paris CARPEM. According to Dr. Laurent-Puig, the “promising results” for the WEE1 inhibitor adavosertib in colorectal cancer in the FOCUS4-C trial could apply to ...
FOCUS4-C Trial: Hint of Activity Reported With Adavosertib in Metastatic Colorectal Cancer
The novel WEE1 inhibitor adavosertib, given after induction chemotherapy, yielded a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with metastatic colorectal cancer and TP53/RAS mutations, according to the randomized phase II FOCUS4-C trial....
Annual Report to the Nation, Part 2: Focus on Patient Economic Burden Associated With Cancer Care
Part 2 of the latest Annual Report to the Nation on the Status of Cancer—provided by the American Cancer Society, National Cancer Institute, Centers for Disease Control and Prevention, and North American Association of Central Cancer Registries—has found that patients with cancer in the United...
Expert Point of View: Federica Di Nicolantonio, MD, PhD
“KRAS G12C inhibitors as monotherapy yield a relatively low overall response rate, but when you combine them with an EGFR [epidermal growth factor receptor] inhibitor, the response rate is nearly double,” said Federica Di Nicolantonio, MD, PhD, Professor of Oncology at the University of Turin in...
ACCURE Trial Aims to Eliminate Disparities in Survival in Black and White Patients With Early-Stage Lung and Breast Cancers
A study presented by Manning et al at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting (Abstract 53) showed that interventions to help Black patients overcome obstacles to completion of treatment can impact disparities in survival outcomes between Black and White patients...
22-Gene Classifier Score May Allow for Personalization of Therapy in Patients With High-Risk Prostate Cancer
A 22-gene genomic classifier (the Decipher score) may be able to predict the course of disease in men with high-risk prostate cancer, according to a patient-level meta-analysis of three randomized clinical trials presented by Paul L. Nguyen, MD, at the 2021 American Society for Radiation Oncology...
Study Examines Relationship Between Risk of Cancer and Age of Smoking Initiation/Cessation
Data from a new study showed that those who started to smoke at earlier ages have an elevated likelihood of dying from cancer. Those who began at the youngest ages (before age 10 years) had four times the cancer mortality rates in adulthood than those who had never smoked. However, individuals who...
Having Stage IV Lung Cancer Has Refocused My Life
The first indication I had stage IV lung cancer was a persistent cough during the beginning of the cold-and-flu season in the fall of 2013. I was 35 years old, never smoked, and in otherwise excellent health, so I ignored the cough for several months until I noticed my breathing had also become...
Clayton Dunklin Pruett, Business Professional, ASCO Member, Dies at Age 86
The delivery of high-quality cancer care relies on a vast network of dedicated experts, some of whom work assiduously behind the scenes, building and modernizing the very architecture on which the cancer community operates. One such person was Clayton Dunklin Pruett, an engineer by training, who...
Zanubrutinib for Relapsed or Refractory Marginal Zone Lymphoma
On September 14, 2021, the Bruton’s tyrosine kinase inhibitor zanubrutinib was granted accelerated approval for adults with relapsed or refractory marginal zone lymphoma (MZL) who have had at least one prior anti-CD20–based regimen.1 Supporting Efficacy Data Approval was based on findings in the...
Acupuncture vs Cognitive Behavioral Therapy for Cognitive Function in Cancer Survivors With Insomnia
Guest Editor’s Note: Cancer-related cognitive difficulties, experienced by many cancer survivors, include perceived or objective deficits in memory, attention, and concentration, which can negatively impact quality of life. Given the important role that healthful sleep plays in cognitive processes, ...
Cardio-oncology
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Urbanization in Bangladesh: The Prevalence of Breast Cancer Brings Unique Challenges
The number of deaths related to breast cancer are increasing at an alarming pace worldwide. According to a World Health Organization (WHO) 2020 report, approximately 2,088,849 new cases and 627,000 deaths related to breast cancer occurred in 2018.1 More than 55% of these deaths occurred in low- to ...
Memorial Sloan Kettering Cancer Center Announces New Early-Career Physician Research Program in Cancer Science
Memorial Sloan Kettering Cancer Center (MSK) recently announced a $25 million gift from Louis V. Gerstner, Jr, to create the Louis V. Gerstner, Jr Physician Scholars Program. Designed to support the innovative research of physician-scientists who are early in their career at MSK, the program will...
An Atypical Road to a Career in Medicine and Leading a Cancer Center for Robert A. Winn, MD
In this installment of the Living a Full Life series, guest editor Jame Abraham, MD, spoke with Robert A. Winn, MD, Director of VCU Massey Cancer Center, Richmond, Virginia. In 2020, he became the first Black physician to lead a National Cancer Institute–designated cancer center. Among other...
Ruxolitinib for Chronic Graft-vs-Host Disease After Failure of Systemic Therapy
On September 22, 2021, ruxolitinib, a tyrosine kinase inhibitor of JAK1 and JAK2 was granted approval for treatment of chronic graft-vs-host disease after failure of one or two lines of systemic therapy in adult and pediatric patients aged ≥ 12 years.1 Supporting Efficacy Data Approval was...
Cabozantinib for Previously Treated Advanced Differentiated Thyroid Cancer
On September 17, 2021, cabozantinib was approved for adult and pediatric patients aged ≥ 12 years with locally advanced or metastatic differentiated thyroid cancer progressing after VEGFR-targeted therapy and who are ineligible or refractory to radioactive iodine.1 Cabozantinib inhibits the...
Tisotumab Vedotin-tftv in Recurrent or Metastatic Cervical Cancer
On September 20, 2021, tisotumab vedotin-tftv, a tissue factor-directed antibody and microtubule inhibitor conjugate, was granted accelerated approval for the treatment of adults with recurrent or metastatic cervical cancer who have had disease progression on or after chemotherapy.1 Supporting...
Expert Point of View: Bruna Pellini, MD
Study discussant Bruna Pellini, MD, of the Department of Thoracic Oncology, Moffitt Cancer Center, Florida, noted that, regardless of PD-L1 or tumor mutation burden status, the NADIM trial demonstrated improved progression-free and overall survival for patients with resectable, stage IIIA non–small ...
Pretreatment Levels of Circulating Tumor DNA May Predict Long-Term Survival in NSCLC
Pretreatment circulating tumor DNA (ctDNA) levels in patients with non–small cell lung cancer (NSCLC) appear to be a more accurate predictor of long-term survival than classic survival surrogates, according to research presented during the International Association for the Study of Lung Cancer...
POSEIDON Trial: Dual Checkpoint Blockade Plus Chemotherapy Improves Survival in First-Line Metastatic NSCLC
The combination of dual checkpoint inhibition plus chemotherapy could be the new standard of care in first-line metastatic non–small cell lung cancer (NSCLC), according to data presented during the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung Cancer.1 ...
Expert Point of View: Heather A. Wakelee, MD, FASCO, and Erika Hlavacek
Heather A. Wakelee, MD, FASCO, President of the International Association for the Study of Lung Cancer (IASLC), who moderated a press briefing where the results of the Atezo-Brain trial were presented, called the study “beautiful work designed specifically” for patients with non–small cell lung...
Phase II Trial Finds Atezolizumab of Benefit in Patients With Lung Cancer and Brain Metastases
Patients with non–small cell lung cancer (NSCLC) and brain metastasis derived significant benefit from treatment with the monoclonal antibody atezolizumab plus chemotherapy, according to the multicenter phase II Atezo-Brain trial.1 The study was presented at the International Association for the...
MSK Announces Appointment of Deb Schrag, MD, FASCO, MPH, as Chair of the Department of Medicine
Deb Schrag, MD, FASCO, MPH, has been named the new Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Dr. Schrag has a deep familiarity with MSK, having previously spent 8 years at the institution as a physician and faculty member. She joins MSK from the...
Expert Point of View: J. Kellogg Parsons, MD, MHS, FACS
“Population-based screening for prostate cancer reduces prostate cancer mortality,” noted J. Kellogg Parsons, MD, MHS, FACS, Professor of Urology, UC San Diego Health, who commented on the study. “Effective screening programs focus on the early detection of aggressive but curable tumors, minimize...
IASLC Presents WCLC 2021 Lectureship Awards to International Array of Lung Cancer Researchers
The International association for the Study of Lung Cancer (IASLC), at its 2021 World Conference on Lung Cancer (WCLC), presented awards to clinicians and researchers who made significant contributions to the treatment of patients with lung cancer. The awards represent many major categories of lung ...
IASLC Names Kristin Richeimer, CAE, DES, Interim Chief Executive Officer
The Board of Directors of the International Association for the Study of Lung Cancer (IASLC) has announced the appointment of Kristin Richeimer, CAE, DES, to the position of Interim Chief Executive Officer (CEO). Ms. Richeimer joined the IASLC in 2010 as its first Director of Membership and brings ...
Michael Diaz, MD, Named President and Managing Physician at Florida Cancer Specialists & Research Institute
Florida Cancer Specialists & Research Institute (FCS) recently appointed Michael Diaz, MD, to the position of President and Managing Physician, effective January 1, 2022. Dr. Diaz succeeds Lucio Gordan, MD, who has served in that position since 2018. Dr. Gordan will continue to practice as a...
STAMPEDE: In Nonmetastatic Castration-Sensitive Prostate Cancer, Abiraterone Added to Androgen-Deprivation Therapy Improves Survival
The addition of 2 years of abiraterone acetate plus prednisolone (AAP) to androgen-deprivation therapy improves metastasis-free survival and overall survival compared with androgen-deprivation therapy alone in men with nonmetastatic castration-sensitive prostate cancer, according to a primary...
Expert Point of View: Florian Lordick, MD, PhD
Florian Lordick, MD, PhD, Professor of Oncology and Director of the University Cancer Center Leipzig, Germany, applauded the positive finding for nivolumab plus chemotherapy in CheckMate 6491 and questioned why nivolumab plus ipilimumab did not meet its endpoint. “I’m calling this a big step...
SECOMBIT Trial Evaluates Optimal Treatment Sequencing in BRAF-Mutated Melanoma
Patients with untreated, metastatic BRAF-mutated melanoma may benefit from receiving immunotherapy first, moving to targeted therapy in the second line, data from the updated overall survival analysis of the randomized, phase II SECOMBIT trial suggest.1 The study aimed to define the optimal...
Expert Point of View: Barbara Pistilli, MD
Barbara Pistilli, MD, of the Breast Cancer Group at Gustave Roussy Cancer Center, Villejuif, France, said the results of the TULIP trial, showing the progression-free survival benefit for vic-trastuzumab duocarmazine (SYD985), help to establish antibody-drug conjugates as key components of the...
Neoadjuvant dd-MVAC Improves Local Control and Progression-Free Survival in Patients With Muscle-Invasive Bladder Cancer
The VESPER phase III trial answers some key questions regarding the optimal management of muscle-invasive bladder cancer. The study found that the neoadjuvant regimen of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (dd-MVAC) was superior to standard gemcitabine/cisplatin in...
Expert Point of View: Johnie Rose, MD, PhD
Invited study discussant, Johnie Rose, MD, PhD, noted that screening is a complex problem that requires balancing the risks of avoidable metastatic prostate cancer with the serious complications associated with treatment. Dr. Rose is Assistant Professor at the Center for Community Health...
Study Assesses Benefit of Digital Health Tools for Cancer Survivors
New study results suggest that to maximize effects of digital support tools for cancer survivors, it is essential to personalize information and increase engagement efforts. The report, published by Leach et al in the journal Cancer, demonstrated significant improvement in the ability to manage...
Two Studies Examine the Efficacy of Immunotherapy for Leptomeningeal Carcinomatosis
Two new studies published in Nature Communications indicate that immunotherapy may benefit people with leptomeningeal carcinomatosis, a rare but serious complication of cancer that has spread to the brain and/or spinal cord. Approximately 5% to 8% of all patients with cancer develop leptomeningeal ...
BTK Inhibition in CLL: An Embarrassment of Riches
Chronic lymphocytic leukemia (CLL) is a B-cell lymphoproliferative disorder defined by a specific phenotype and the presence of more than 5,000 clonal B cells in the peripheral blood.1 In the absence of this number of circulating cells, its soft-tissue/bone-marrow counterpart is semantically...
Expert Point of View: Gonzalo Gomez-Abuin, MD, and Gabriel N. Hortobagyi, MD, MACP, FASCO
The invited discussant of the MONALESSA-2 trial was Gonzalo Gomez-Abuin, MD, a medical oncologist who is Head of the Clinical Research Unit at Hospital Alemán in Buenos Aires. According to Dr. Gomez-Abuin, phase III trials of three different CDK4/6 inhibitors—ribociclib, palbociclib, and...
MONALEESA-2: Overall Survival Benefit With First-Line Ribociclib Plus Letrozole
Ribociclib plus hormonal therapy in the first-line setting boosted overall survival by more than 1 year, vs hormone therapy alone, in postmenopausal women with hormone receptor–positive HER2-negative advanced breast cancer, according to the latest findings from the MONALEESA-2 trial, reported at...
Overall Survival in the MAIA Trial: Daratumumab, Lenalidomide, and Dexamethasone for Newly Diagnosed Transplant-Ineligible Patients With Multiple Myeloma
As reported in The Lancet Oncology by Thierry Facon, MD, and colleagues, an interim analysis of overall survival in the pivotal phase III MAIA trial has shown a significant benefit with the addition of daratumumab to lenalidomide/dexamethasone in newly diagnosed, transplant-ineligible patients with ...
